Gross Profit Trends Compared: Perrigo Company plc vs Amphastar Pharmaceuticals, Inc.

Pharma Giants' Profit Trends: Perrigo vs. Amphastar

__timestampAmphastar Pharmaceuticals, Inc.Perrigo Company plc
Wednesday, January 1, 2014512560001447700000
Thursday, January 1, 2015773470001712400000
Friday, January 1, 20161041890002051800000
Sunday, January 1, 2017907950001979500000
Monday, January 1, 20181069850001831500000
Tuesday, January 1, 20191319230001773300000
Wednesday, January 1, 20201433400001815200000
Friday, January 1, 20211997390001416200000
Saturday, January 1, 20222488600001455400000
Sunday, January 1, 20233511210001680400000
Loading chart...

Unleashing the power of data

Gross Profit Trends: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This chart compares the gross profit trajectories of Perrigo Company plc and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Perrigo, a global leader in over-the-counter health products, consistently outperformed Amphastar, a specialty pharmaceutical company, in terms of gross profit. However, Amphastar's growth rate is noteworthy, with a staggering 585% increase over the decade, from approximately $51 million in 2014 to $351 million in 2023. In contrast, Perrigo's gross profit peaked in 2016 at around $2 billion, before stabilizing around $1.7 billion in recent years. This data highlights Amphastar's aggressive growth strategy and Perrigo's steady market presence. Investors and industry analysts should watch these trends closely as they reflect broader market dynamics and strategic shifts within the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025